[Effect of decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C on indices of hepatic fibrosis in chronic hepatitis B].
OBJECTIVE
To evaluate the effect of decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C on the indices of hepatic fibrosis in chronic hepatitis B.


METHODS
The 94 cases of chronic viral hepatitis B patients were randomly divided into two groups. The treatment group was treated with stronger neo-minophagen C 100 mL dissolved in 10% dextrose 250 ml once a day intravenously, combined with decoction of turtle shell for anti-fibrosis one powder daily. And the control group was treated with stronger neo-minophagen C alone, 3 months as a course. Liver fibrosis indexes and liver function index were tested for two groups of patients before and after the treatment.


RESULTS
Both the difference of liver fibrosis indexes between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P < 0.01). Both the difference of liver function index between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P < 0.01). The basic cure rate and total effective rate were 40% and 84.0% in the treatment group and 27.27% and 86.18% in the control group respectively with significant difference. The treatment group was superior to control group in the mean size of diameter of portal vein and the thickness of spleen (P < 0.01).


CONCLUSIONS
Decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C could significantly improve the clinical efficacy and the liver fibrosis indexes and liver function index in chronic hepatitis B.
South Hospital, The First Hospital of Manchuria, Manchuria 021400, China.
Lijuan
L
Zhang
Yijie
Y
Chang
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D060105:Animal Shells / Q000737:chemistry*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D003545:Cysteine / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005998:Glycine / Q000008:administration & dosage / Q000627:therapeutic use*; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods; D008875:Middle Aged; D014020:Tissue Extracts / Q000627:therapeutic use*; D016896:Treatment Outcome; D014426:Turtles; D005723:gamma-Glutamyltransferase / Q000097:blood
D004338:Drug Combinations; D014020:Tissue Extracts; C083319:stronger neominophagen C; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003545:Cysteine; D006034:Glycyrrhetinic Acid; D005998:Glycine